Ovid Therapeutics
- Health
Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome
Osaka, Japan & New York, United States: − Ovid eligible to receive up to $856M in payments, including a $196M…
Read More »